- Home
- HSCS vs TOVX Comparison
HSCS vs TOVX Comparison
Compare HSCS & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSCS
- TOVX
- Stock Information
- Founded
- HSCS 2007
- TOVX 2001
- Country
- HSCS United States
- TOVX United States
- Employees
- HSCS N/A
- TOVX N/A
- Industry
- HSCS Medical Specialities
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- HSCS Health Care
- TOVX Health Care
- Exchange
- HSCS Nasdaq
- TOVX Nasdaq
- Market Cap
- HSCS 3.5M
- TOVX 3.6M
- IPO Year
- HSCS 2022
- TOVX 2006
- Fundamental
- Price
- HSCS $3.43
- TOVX $0.53
- Analyst Decision
- HSCS Strong Buy
- TOVX Hold
- Analyst Count
- HSCS 2
- TOVX 1
- Target Price
- HSCS $13.00
- TOVX N/A
- AVG Volume (30 Days)
- HSCS 13.9K
- TOVX 2.5M
- Earning Date
- HSCS 03-13-2025
- TOVX 05-20-2025
- Dividend Yield
- HSCS N/A
- TOVX N/A
- EPS Growth
- HSCS N/A
- TOVX N/A
- EPS
- HSCS N/A
- TOVX N/A
- Revenue
- HSCS N/A
- TOVX N/A
- Revenue This Year
- HSCS N/A
- TOVX N/A
- Revenue Next Year
- HSCS N/A
- TOVX N/A
- P/E Ratio
- HSCS N/A
- TOVX N/A
- Revenue Growth
- HSCS 261.17
- TOVX N/A
- 52 Week Low
- HSCS $2.36
- TOVX $0.74
- 52 Week High
- HSCS $13.50
- TOVX $12.25
- Technical
- Relative Strength Index (RSI)
- HSCS 54.77
- TOVX 21.24
- Support Level
- HSCS $3.38
- TOVX $1.32
- Resistance Level
- HSCS $3.62
- TOVX $1.45
- Average True Range (ATR)
- HSCS 0.23
- TOVX 0.15
- MACD
- HSCS 0.00
- TOVX -0.09
- Stochastic Oscillator
- HSCS 39.46
- TOVX 5.82
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.